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Introduction  
Unilateral pleural effusions are a common diagnostic challenge for the respiratory physician. In the 
majority a diagnosis can be made after medical history, computerised tomography (CT) and pleural 
fluid analysis [1]. A proportion of patients will require a pleural biopsy but following this a minority 
will remain undiagnosed and are defined as idiopathic/inflammatory pleuritis (IP) [2]. These patients 
often require extended follow up to ensure effusion resolution and exclude malignancy. 
A previous prospective study proposed a possible causative role of Epstein-Barr virus (EBV) in 
“unexplained” pleural effusions after finding that nearly 60% had evidence of EBV-DNA within the 
pleural fluid [3]. 
This hypothesis has not been validated in an external cohort. Our aim was to determine the 
presence and quantity of EBV in the pleural fluid and serum of patients with ‘undiagnosed’ pleural 




Patients presenting with undiagnosed pleural effusions were prospectively recruited to this single 
centre UK based observational study and consented to having serum and pleural fluid stored. All 
were assigned a 12-month diagnosis as to the most likely cause of their effusion. The final diagnosis 
was agreed by two independent respiratory consultants. A diagnosis of IP required histocytological 
evidence (biopsy negative for malignancy), in the absence of markers of infection (significantly raised 
white blood cells or C-reactive protein) or a known history of asbestos exposure (to exclude cases of 
parapneumonic effusion or benign asbestos related pleural effusions respectively). The full 
diagnostic criteria used in the study have been previously published [4].  
Patients with final diagnosis of IP had pleural fluid and serum analysed for the presence of EBV. A 
selection of controls, matched by presentation date, of transudative effusions (cardiac, liver or renal 
failure) and parapneumonic effusions were also analysed. 
 
DNA isolation and PCR 
Samples were stored in a -70-degree freezer and analysed en-bloc. Nucleic acids were extracted 
from pleural fluid and serum using the Qiagen DSP virus/pathogen extraction kit according to 
manufacturer instructions (Qiagen, Dusseldorf, Germany). In-house real time PCR was performed (in 
duplicate) using nucleic acid extracts spiked with T4 phage as internal control, TaqMan Fast 
Universal PCR Master Mix, and in-house EBV primers [5]. EBV-DNA levels were estimated from the 
crossing threshold (Ct value) at which DNA amplification became detectable (the limit of detection is 
about is approximately 1000 copies/mL). 
 
Serology 
EBV serology was performed using the DiaSorin LIAISON© XL platform, testing for anti-EBV 
antibodies using the EBV IgM, VCA IgG (Epstein-Barr virus capsid antigen), EBNA IgG (Epstein-Barr 
virus nuclear antigen) reagents.  
 
Statistical analysis  
Continuous data are expressed as medians (with ranges) and compared using a Mann-Whitney U-




Between 2008-2017, 1005 consecutive patients with a new pleural effusion were enrolled and had a 
12-month diagnosis. IP was diagnosed in 27 cases (3%). The median age was 70 years (range 53- 92) 
and there was a male predominance (23/27, 85%), see Table 1. The presence of EBV was assessed in 
these and 163 controls (54 transudates, 109 parapneumonic effusions). EBV-DNA was found in the 
pleural fluid of 14.8% (4/27) of IP cases compared to 13.8% (15/109) parapneumonic and 5.6% 
(3/54) transudative effusions. Ct values across all groups were high ranging from 33.8 to 41.2, 
indicating the presence of low levels of EBV-DNA. There was no significant difference in pleural fluid 
EBV levels depending on effusion aetiology or predominant cell types (p- 0.183 and p-0.248 
respectively, using Mann-Whitney U-test). The analysis was repeated using the qualitative EBV PCR 
results with no relationship found between the same groups (p-0.354 and p-0.701 respectively, using 
Fisher’s exact test).   
Serological testing and serum EBV PCR was performed for cases where pleural fluid EBV-DNA was 
detected.  All cases showed evidence of past EBV infection; none had detectable EBV IgM. On PCR, 
EBV-DNA was found in low levels in the serum of 5 cases, all of whom had a final diagnosis of 
parapneumonic effusion.  
 
Discussion 
This study did not find evidence of EBV as a causative factor in the development of IP. A previous 
cohort study published by Thijsen in the European Respiratory Journal found EBV-DNA in the pleural 
fluid of 40% of a 60-patient cohort with all-cause effusions [3]. The prevalence of positive pleural 
fluid EBV-DNA was higher in the 34 patients with ‘unexplained’ pleural effusions. This prompted the 
authors to suggest that EBV reactivation might have a causative role in their development. This 
current study attempted to validate these findings using a 190 patient cohort in whom IP was only 
diagnosed after a biopsy and 12 months of radiological follow up.  
EBV or human herpesvirus 4 infections are very common and by adulthood around 90% of 
individuals have been infected [6]. Acute infection is usually asymptomatic in the immunocompetent 
or can manifest itself as infectious mononucleosis. Following the acute phase, B lymphocytes 
become latently infected and EBV can persist with low/intermittent virion production. Reactivation 
within the lung can occur usually resulting from immunosuppression. A series of 20 cases of EBV-
DNA-positive pleural effusions was published by Takei and colleagues [7]. All cases had a history of 
lung transplantation but EBV loads were relatively low.  
EBV as a possible causative agent in pleural effusions is a plausible concept for a number of reasons. 
Firstly, some effusions will remain undiagnosed despite conventional histocytological investigations. 
Secondly, those presenting with pleural effusions might be immunocompromised due to age and/or 
immunosuppressive medications. Finally, the course of exudative effusions can be relapsing and 
remitting suggesting a reactivating viral process.  
We examined a cohort of patients in whom the diagnosis was elusive despite pleural fluid analysis, 
imaging follow-up and histological biopsy. These patients were termed as having IP (literature terms 
include idiopathic, inflammatory, non-specific or fibrous pleuritis) and require fastidious follow up to 
exclude malignancy. Previous retrospective studies have found that 12-18% of cases of IP at initial 
biopsy have an underlying malignant cause [8, 9]. Identifying the other causes would be extremely 
useful for risk stratification.  In this study, patients were diagnosed with IP after at least 1 year of 
follow up, no known history of asbestos exposure (to exclude benign asbestos pleural effusions), and 
a non-diagnostic pleural biopsy result. All cases were stable or resolved at 1 year and are therefore 
truly idiopathic.  
In 15% of the IP cases, EBV was present within pleural fluid but at only very low levels. This 
prevalence was not significantly different to the infected or transudative controls. Additionally, there 
was no serological evidence of recent or reactivated EBV in cases with pleural fluid positive for EBV. 
We hypothesize that the low-levels of EBV DNA found in these pleural fluid samples may be a result 
of latently infected B lymphocytes without a pathological role.  
In conclusion, we found no evidence that EBV was a causative factor in cases of IP and testing for 




Table 1- Patient demographics 






Median age (range) 68 (53-92) 63 (18-95) 78 (55-97) 
Male/Female (n) 23/4 70/39 32/22 
Median duration of symptoms in 
months (range)  
3 (0.2-12) 0.2 (0.1-3) 4 (0.1- 24) 
Laterality (R/L/Bilateral) 18 / 7 / 2 57/ 44 / 8 31/ 6 / 17 
Mean CRP mg/L (range) 17 (1-70) 145 (8-429) 24 (1-75) 
Pleural fluid analysis 
• Lymphocytic 














 22 (41%) 
0 (0%) 
 4 (7%) 
28 (52%) 
Mean pleural fluid protein g/L 
(range) 
44 (24-59) 43 (17-68) 23 (12-31)  
    
Presence of pleural fluid EBV-DNA 
 
4/27 (14.8%) 15/109 (13.8%)  3/54 (5.6%) 
Ct median (range) *  36.5 (34.5-38.9) 36.8 (33.8-41.1) 37.2 (36.0-37.8) 
Cell differentials definitions: Neutrophilic >50%, Lymphocytic effusion >50%, Eosinophilic >10%, Mixed- no 
predominant cell type. *when pleural fluid EBV detected 
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